Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Juno Therapeutics will collect $50 million now that Celgene has exercised an option to develop its cellular therapies targeting CD19 outside of North America and China. Juno’s CD19 portfolio includes three drug candidates; one, JCAR015, is in Phase II studies to treat acute lymphoblastic leukemia. Last year, Celgene paid $1 billion for the rights to opt in to Juno’s cellular therapies. Separately, Juno and WuXi AppTec have started JW Biotechnology in China to pair Juno’s cellular therapy technology with WuXi’s R&D and manufacturing expertise.
This article has been sent to the following recipient: